Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bruton’s Tyrosine Kinase Inhibition Promotes Myelin Repair
Elodie Martin, Marie‐Stéphane Aigrot, Roland Grenningloh, et al.
Brain Plasticity (2020) Vol. 5, Iss. 2, pp. 123-133
Open Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

Smouldering multiple sclerosis: the ‘real MS’
Gavin Giovannoni, Veronica Popescu, Jens Wuerfel, et al.
Therapeutic Advances in Neurological Disorders (2022) Vol. 15
Open Access | Times Cited: 174
Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances
Amit Bar‐Or, Rui Li
The Lancet Neurology (2021) Vol. 20, Iss. 6, pp. 470-483
Closed Access | Times Cited: 150
Multiple sclerosis: Neuroimmune crosstalk and therapeutic targeting
Marc Charabati, Michael A. Wheeler, Howard L. Weiner, et al.
Cell (2023) Vol. 186, Iss. 7, pp. 1309-1327
Open Access | Times Cited: 117
Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis
Heather Yong, V. Wee Yong
Nature Reviews Neurology (2021) Vol. 18, Iss. 1, pp. 40-55
Closed Access | Times Cited: 116
Bruton tyrosine kinase inhibitors for multiple sclerosis
Julia Krämer, Amit Bar‐Or, Timothy J. Turner, et al.
Nature Reviews Neurology (2023) Vol. 19, Iss. 5, pp. 289-304
Open Access | Times Cited: 98
Multiple Sclerosis: Inflammatory and Neuroglial Aspects
Giulio Papiri, Giordano D’Andreamatteo, Gabriella Cacchiò, et al.
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 2, pp. 1443-1470
Open Access | Times Cited: 45
BTK inhibition limits B-cell–T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy
Rui Li, Hao Tang, Jeremy C. Burns, et al.
Acta Neuropathologica (2022) Vol. 143, Iss. 4, pp. 505-521
Open Access | Times Cited: 46
Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders
Franz Felix Konen, Nora Möhn, Torsten Witte, et al.
Autoimmunity Reviews (2023) Vol. 22, Iss. 5, pp. 103312-103312
Open Access | Times Cited: 30
BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair
Anastasia Geladaris, Sebastian Torke, Darius Saberi, et al.
Acta Neuropathologica (2024) Vol. 147, Iss. 1
Open Access | Times Cited: 14
Bruton’s Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy
Antonio García‐Merino
Cells (2021) Vol. 10, Iss. 10, pp. 2560-2560
Open Access | Times Cited: 41
Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models
Michael Dietrich, Christina Hecker, Elodie Martin, et al.
Neurology Neuroimmunology & Neuroinflammation (2022) Vol. 9, Iss. 3
Open Access | Times Cited: 30
Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?
Anastasia Geladaris, Sebastian Torke, Martin S. Weber
CNS Drugs (2022) Vol. 36, Iss. 10, pp. 1019-1030
Open Access | Times Cited: 30
B cell targeted therapies in inflammatory autoimmune disease of the central nervous system
Moritz J. Furman, Sven G. Meuth, Philipp Albrecht, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 21
Sex differences of microglia in the healthy brain from embryonic development to adulthood and across lifestyle influences
Bianca Caroline Bobotis, Olivia Braniff, Makenna Gargus, et al.
Brain Research Bulletin (2023) Vol. 202, pp. 110752-110752
Open Access | Times Cited: 17
Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors
Sarah Dybowski, Sebastian Torke, Martin S. Weber
JAMA Neurology (2023) Vol. 80, Iss. 4, pp. 404-404
Closed Access | Times Cited: 16
Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease
Stefan F. H. Neys, Jasper Rip, Rudi W. Hendriks, et al.
Drugs (2021) Vol. 81, Iss. 14, pp. 1605-1626
Open Access | Times Cited: 40
Bruton’s Tyrosine Kinase Inhibition in Multiple Sclerosis
Raphaël Schneider, Jiwon Oh
Current Neurology and Neuroscience Reports (2022) Vol. 22, Iss. 11, pp. 721-734
Open Access | Times Cited: 27
Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis
Neeta Garg, Elizabeth Jordan Padron, Kottil Rammohan, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 20, pp. 6139-6139
Open Access | Times Cited: 26
Pathways to cures for multiple sclerosis: A research roadmap
Bruce F. Bebo, Mark Allegretta, Douglas Landsman, et al.
Multiple Sclerosis Journal (2022) Vol. 28, Iss. 3, pp. 331-345
Open Access | Times Cited: 24
Role of Microglial Cells in the Pathophysiology of MS: Synergistic or Antagonistic?
Hubert Mado, Monika Adamczyk‐Sowa, Paweł Sowa
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 1861-1861
Open Access | Times Cited: 15
Bruton’s tyrosine kinase-bearing B cells and microglia in neuromyelitis optica spectrum disorder
Ye Liu, Zhenning Huang, Tianxiang Zhang, et al.
Journal of Neuroinflammation (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 13
Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study
Xavier Montalbán, Karolina Piasecka-Stryczyńska, Jens Kühle, et al.
Multiple Sclerosis Journal (2024) Vol. 30, Iss. 4-5, pp. 558-570
Open Access | Times Cited: 5
A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis
Laura Airas, Robert Bermel, Tanuja Chitnis, et al.
Therapeutic Advances in Neurological Disorders (2024) Vol. 17
Open Access | Times Cited: 5
Microglia: The Missing Link to Decipher and Therapeutically Control MS Progression?
Anastasia Geladaris, Darius Häusler, Martin S. Weber
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 7, pp. 3461-3461
Open Access | Times Cited: 29
Disease-modifying strategies: Targeting protein kinases in multiple sclerosis and other autoimmune disorders
Franz Felix Konen, Nora Möhn, Torsten Witte, et al.
Autoimmunity Reviews (2025) Vol. 24, Iss. 4, pp. 103754-103754
Closed Access
Page 1 - Next Page

Scroll to top